| Mean age [years] [mean ± SD] | 35 ± 11 |
| Males [n] [%] | 58 [62.36] |
| Family history of IBD [n] [%] | 7 [7.52] |
| Co-morbid illnesses [n] [%] | |
| Diabetes mellitus | 3 [3.22] |
| Hypertension | 2 [2.15] |
| Others | 5 [5.37] |
| Disease duration [years] [mean ± SD] | 5.15 ± 4.62 |
| Disease extent [n] [%] a | |
| E1 | 18 [19.35] |
| E2 | 44 [47.31] |
| E3 | 31 [33.33] |
| Disease severity [n] [%] | |
| Moderate [Mayo clinic score 6–9] | 71 [76.34] |
| Severe [Mayo clinic score ≥ 10] | 22 [23.65] |
| Mayo clinic score [mean ± SD] | 8.07 ± 2.00 |
| Endoscopic Mayo score [mean ± SD] | 2.50 ± 0.50 |
| Endoscopic Mayo score [n] [%] | |
| 2 | 46 [49.46] |
| 3 | 47 [50.53] |
| Concomitant medications at the time of enrolment [n] [%] | |
| 5-ASAb,c | 93 [100] |
| Azathioprined | 48 [51.61] |
| Corticosteroidse | 73 [78.49] |
| Biologics | Nil |
| Previous exposure to anti-TNF therapy [n] [%] | 19 [20.43] |
| Prior exposure to multiple biologics [n] [%] | Nil |
| Mean age [years] [mean ± SD] | 35 ± 11 |
| Males [n] [%] | 58 [62.36] |
| Family history of IBD [n] [%] | 7 [7.52] |
| Co-morbid illnesses [n] [%] | |
| Diabetes mellitus | 3 [3.22] |
| Hypertension | 2 [2.15] |
| Others | 5 [5.37] |
| Disease duration [years] [mean ± SD] | 5.15 ± 4.62 |
| Disease extent [n] [%] a | |
| E1 | 18 [19.35] |
| E2 | 44 [47.31] |
| E3 | 31 [33.33] |
| Disease severity [n] [%] | |
| Moderate [Mayo clinic score 6–9] | 71 [76.34] |
| Severe [Mayo clinic score ≥ 10] | 22 [23.65] |
| Mayo clinic score [mean ± SD] | 8.07 ± 2.00 |
| Endoscopic Mayo score [mean ± SD] | 2.50 ± 0.50 |
| Endoscopic Mayo score [n] [%] | |
| 2 | 46 [49.46] |
| 3 | 47 [50.53] |
| Concomitant medications at the time of enrolment [n] [%] | |
| 5-ASAb,c | 93 [100] |
| Azathioprined | 48 [51.61] |
| Corticosteroidse | 73 [78.49] |
| Biologics | Nil |
| Previous exposure to anti-TNF therapy [n] [%] | 19 [20.43] |
| Prior exposure to multiple biologics [n] [%] | Nil |
aE1: proctitis, **E2: left-sided colitis, ***E3: pancolitis.
b5-ASA: 5-aminosalicylic acid.
c5-ASA: median dose 4.8 g/day [range 2.4–4.8 g/day].
dAzathioprine: median dose 100 mg/day [range 50–150 mg/day].
eCorticosteroids: prednisolone; median dose 20 mg [range 10–40 mg].
| Mean age [years] [mean ± SD] | 35 ± 11 |
| Males [n] [%] | 58 [62.36] |
| Family history of IBD [n] [%] | 7 [7.52] |
| Co-morbid illnesses [n] [%] | |
| Diabetes mellitus | 3 [3.22] |
| Hypertension | 2 [2.15] |
| Others | 5 [5.37] |
| Disease duration [years] [mean ± SD] | 5.15 ± 4.62 |
| Disease extent [n] [%] a | |
| E1 | 18 [19.35] |
| E2 | 44 [47.31] |
| E3 | 31 [33.33] |
| Disease severity [n] [%] | |
| Moderate [Mayo clinic score 6–9] | 71 [76.34] |
| Severe [Mayo clinic score ≥ 10] | 22 [23.65] |
| Mayo clinic score [mean ± SD] | 8.07 ± 2.00 |
| Endoscopic Mayo score [mean ± SD] | 2.50 ± 0.50 |
| Endoscopic Mayo score [n] [%] | |
| 2 | 46 [49.46] |
| 3 | 47 [50.53] |
| Concomitant medications at the time of enrolment [n] [%] | |
| 5-ASAb,c | 93 [100] |
| Azathioprined | 48 [51.61] |
| Corticosteroidse | 73 [78.49] |
| Biologics | Nil |
| Previous exposure to anti-TNF therapy [n] [%] | 19 [20.43] |
| Prior exposure to multiple biologics [n] [%] | Nil |
| Mean age [years] [mean ± SD] | 35 ± 11 |
| Males [n] [%] | 58 [62.36] |
| Family history of IBD [n] [%] | 7 [7.52] |
| Co-morbid illnesses [n] [%] | |
| Diabetes mellitus | 3 [3.22] |
| Hypertension | 2 [2.15] |
| Others | 5 [5.37] |
| Disease duration [years] [mean ± SD] | 5.15 ± 4.62 |
| Disease extent [n] [%] a | |
| E1 | 18 [19.35] |
| E2 | 44 [47.31] |
| E3 | 31 [33.33] |
| Disease severity [n] [%] | |
| Moderate [Mayo clinic score 6–9] | 71 [76.34] |
| Severe [Mayo clinic score ≥ 10] | 22 [23.65] |
| Mayo clinic score [mean ± SD] | 8.07 ± 2.00 |
| Endoscopic Mayo score [mean ± SD] | 2.50 ± 0.50 |
| Endoscopic Mayo score [n] [%] | |
| 2 | 46 [49.46] |
| 3 | 47 [50.53] |
| Concomitant medications at the time of enrolment [n] [%] | |
| 5-ASAb,c | 93 [100] |
| Azathioprined | 48 [51.61] |
| Corticosteroidse | 73 [78.49] |
| Biologics | Nil |
| Previous exposure to anti-TNF therapy [n] [%] | 19 [20.43] |
| Prior exposure to multiple biologics [n] [%] | Nil |
aE1: proctitis, **E2: left-sided colitis, ***E3: pancolitis.
b5-ASA: 5-aminosalicylic acid.
c5-ASA: median dose 4.8 g/day [range 2.4–4.8 g/day].
dAzathioprine: median dose 100 mg/day [range 50–150 mg/day].
eCorticosteroids: prednisolone; median dose 20 mg [range 10–40 mg].
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
